Mood changes come up often with GLP-1 medicines. Here is how the studies are built, why they disagree, and what you can do with that information.
GLP-1 mood side effects come up often in clinic visits, online groups, and news stories. Many people want to know whether these medicines affect anxiety or depression. Reading the evidence takes some care, because a headline and a proven cause are not the same thing. This guide explains how the studies are built, why they sometimes disagree, and what you can do with that information.
Why the question keeps coming back
Patients mention irritability and low mood, and the press covers the topic regularly. That attention is worth noticing, but it is not proof. Three things get mixed up often. A safety signal is a pattern someone flagged for a closer look. A statistical association means two things show up together more often than expected. A proven cause means a controlled comparison showed the drug produces the effect.
There is also a biological reason to study this. GLP-1 receptors are found in brain regions tied to appetite and reward, including parts of the hypothalamus and brainstem. That makes mood a plausible research question. It does not show that the drug changes mood.
What the regulators reviewed
In 2024, the European Medicines Agency’s safety committee (PRAC) and the U.S. Food and Drug Administration both reviewed reports of suicidal thoughts and behavior in people using these medicines. Neither agency established a causal link. Check the exact conclusions and dates directly on the agency websites, because wording and labels can change. If you want to follow those updates over time, OzemNews at ozemnews.com covers new notices as they appear.
Spontaneous adverse event reports are one tool. Doctors, patients, and manufacturers send them when they suspect a link. They help spot unusual patterns, but they cannot show how common an event is or whether the drug caused it, because there is no comparison group. Controlled trials randomize people to drug or placebo, which makes comparison fairer.
Both agencies also called for continued monitoring. A label warning is a precaution. It tells prescribers to watch for something, and it does not confirm an effect.
What the randomized trials recorded
The STEP trials for semaglutide and the SURMOUNT trials for tirzepatide recorded psychiatric adverse events as part of their safety data. Many of these programs, however, excluded people with recent severe depression, recent suicidal thoughts, or certain psychiatric diagnoses. That is common for safety reasons, but it limits what the results can say about those groups.
When reading a trial, look at the placebo arm first. Mood symptoms also appear in people taking placebo, since people joining a weight study bring their own stress and sleep problems. The useful comparison is drug against placebo, not the drug arm alone.
Check the confidence intervals too. Psychiatric events are relatively uncommon in these trials, so small counts produce wide intervals. A “not significant” result may just mean there were too few events to be sure. The exact rates are in the source tables of the primary publications in the New England Journal of Medicine or The Lancet.
Real-world studies and why they disagree
Large observational studies use health system databases, national registries, and veterans’ cohorts. They follow people taking these drugs and compare them with people who are not, looking at depression, anxiety, and self-harm. Their size and long follow-up are strengths. Nobody randomized the treatment, though, and that creates problems.
The biggest one is confounding by indication. People prescribed these drugs often differ in body weight, diabetes severity, and psychiatric history. Researchers adjust for what they can measure, but anything unrecorded can distort results. Reverse causation adds more noise, since depression itself can change appetite and treatment adherence. The comparator matters as well. A result can shift depending on whether the drug is compared with placebo, another diabetes medicine, or another weight-loss medicine.
Some studies report associations in one direction, others find none, and a few point the other way. That pattern is normal in a young field, and a single study should not settle the question. For each study, note the design, comparator, follow-up length, and whether prior psychiatric diagnoses were adjusted for. PubMed at pubmed.ncbi.nlm.nih.gov is the place to find these details. Readers who want to keep up with new observational studies can also follow OzemNews as those papers come out.
Why weight loss itself might change mood
Several non-drug pathways could matter. Better sleep is one, especially in people whose sleep apnea improves with weight loss. Changes in body image, steadier blood sugar, and lower systemic inflammation are other proposed links. Each is a hypothesis that needs direct testing.
Reports of fewer food cravings and quieter “food noise” are interesting. Still, most come from self-reports without a control group. Studies using validated craving scales against a comparison group are needed before anyone can separate the drug effect from expectation.
The evidence does not show these drugs work as antidepressants. They are not approved to treat mood disorders, and no trial has established a treatment effect for depression or anxiety.
What a patient on treatment can do
Start with a simple mood and sleep log. Each day, record the date, your current dose, and any changes in mood, irritability, anxiety, or sleep. Patterns often show up after a few weeks, such as symptoms clustering after a dose increase. Bring that log to your next appointment, because specific notes help your prescriber far more than a general “I’ve felt off lately.” A reliable reading list like OzemNews can help you prepare questions before the visit.
Before starting, tell your prescriber about any history of:
- depression or anxiety
- eating disorders
- suicidal thoughts or self-harm
- psychiatric medicines you currently take
Do not stop the medicine abruptly on your own. Changes should happen with medical guidance.
Some symptoms need immediate action. Any thoughts of harming yourself call for help now. In Brazil, call SAMU at 192 or the fire department at 193 for emergencies, or call CVV at 188, a free line open 24 hours. Tell someone you trust and do not stay alone with those thoughts.
The question “is this the drug or something else?” usually needs a clinician. Mood symptoms have many causes, including thyroid problems, sleep disorders, stress, and other medicines.
Open questions and what would settle them
Several gaps remain. Trial periods are shorter than the time many people spend on these drugs, so long-term mood data are limited. People with severe psychiatric illness were often excluded, so their outcomes are poorly characterized. Differences between drugs in the same class are also unclear.
The most useful next studies would include people with stable psychiatric conditions and use validated mood and anxiety scales at several time points. Researchers can check registered trials on ClinicalTrials.gov at clinicaltrials.gov to see which ones list mood or anxiety as an outcome.
Here is where things stand. Regulators reviewed suicidal thoughts reports without establishing causation, but they asked for monitoring. Trials recorded psychiatric events while excluding some higher-risk groups. Observational studies disagree because of confounding and comparator choices. Weight loss may affect mood through sleep and body image, but that remains a hypothesis. What is still unknown is how much of any mood change comes from the drug itself, and who is most affected.
FAQ
Do GLP-1 drugs cause anxiety?
The evidence does not establish that they cause anxiety. Reports, observational studies, and trials have raised questions, but the answer is not settled. If you notice new anxiety, talk with your prescriber.
Did regulators find that GLP-1 drugs cause suicidal thoughts?
The 2024 EMA and FDA reviews did not establish a causal link. Both called for continued monitoring, and label warnings are precautions, not confirmed effects.
Can semaglutide or tirzepatide treat depression?
No. These medicines are approved for diabetes and weight management, and the evidence does not show they work as antidepressants.
What should I do if my mood changes after starting treatment?
Record the date, dose, and symptoms, then contact your prescriber soon. If you have any thoughts of self-harm, call 192, 193, or CVV at 188 in Brazil right away.
Sources
Disclaimer: This content is for informational purposes only and does not replace professional medical advice. Always consult your doctor before starting, changing or stopping any treatment.
Ozempro — Monitor GLP-1
You don't have to go through this alone
Connect with people on the same GLP-1 journey: support, motivation and real stories from those who get it.
or download the app
